Mounjaro vs Ozempic 2026: Which GLP-1 Is Actually Better?

Mounjaro and Ozempic are both weekly injectable GLP-1 medications — but they’re not the same drug, and they don’t produce the same results. If you’re trying to decide between them (or figure out which is covered by your insurance), here’s the complete picture for 2026.

The Key Difference in One Sentence

Ozempic targets one receptor (GLP-1). Mounjaro targets two (GLP-1 + GIP). That dual action is why Mounjaro consistently outperforms Ozempic on both blood sugar control and weight loss.

Side-by-Side Comparison

Factor	Mounjaro (Tirzepatide)	Ozempic (Semaglutide)
Manufacturer	Eli Lilly	Novo Nordisk
Mechanism	GLP-1 + GIP dual agonist	GLP-1 agonist only
FDA approved for	Type 2 diabetes	Type 2 diabetes
Weight loss FDA approval	Zepbound (same drug)	Wegovy (same drug, higher dose)
Injection frequency	Once weekly	Once weekly
Avg weight loss (type 2 diabetes)	~15–22% body weight	~6–10% body weight
A1C reduction	Up to 2.5% reduction	Up to 1.9% reduction
Retail price (no insurance)	~$1,069/mo	~$935/mo
Compounded equivalent	Compounded tirzepatide (~$150–350/mo)	Compounded semaglutide (~$99–250/mo)
Long-term CV outcome data	SURPASS-CVOT (ongoing)	SUSTAIN-6 + SELECT (both positive)

Weight Loss: Mounjaro Is the Clear Winner

In the SURPASS clinical trial program, tirzepatide (Mounjaro) produced significantly greater weight loss than semaglutide across head-to-head comparisons:

• SURPASS-2 (direct comparison): Tirzepatide 15mg caused average 12.4 lbs more weight loss than semaglutide 1mg in people with type 2 diabetes
• People without diabetes doing Mounjaro vs Ozempic equivalent (Zepbound vs Wegovy) see roughly 22.5% vs 14.9% weight loss on maximum doses
• Non-responder rate (losing less than 5%): ~5% on tirzepatide vs ~14% on semaglutide

Blood Sugar Control: Also Mounjaro

In the SURPASS-2 trial comparing tirzepatide directly to semaglutide 1mg in type 2 diabetes patients:

• A1C reduction: 2.01–2.30% (tirzepatide) vs 1.86% (semaglutide)
• More patients reached A1C below 7%: 82–86% (tirzepatide) vs 74% (semaglutide)
• More patients reached A1C below 5.7% (normal range): 27–46% (tirzepatide) vs 19% (semaglutide)

Side Effects: Similar Profiles

Both share the core GI side effect profile — nausea, diarrhea, constipation, vomiting — because they both activate GLP-1 receptors. In SURPASS-2, Mounjaro had slightly higher rates of nausea and diarrhea at higher doses, but the difference was modest and side effects resolved similarly for both drugs.

Both carry the same boxed warning about thyroid C-cell tumors and are contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or MEN2.

Insurance Coverage

Both Mounjaro and Ozempic are FDA-approved for type 2 diabetes only (their weight-loss branded equivalents — Zepbound and Wegovy — are the obesity-approved versions). For people with type 2 diabetes:

• Both are commonly covered by commercial insurance with prior authorization
• Medicare Part D coverage for diabetes medications generally includes both
• Specific formulary placement varies by plan — Mounjaro might be preferred on some plans, Ozempic on others
• Check your specific plan’s formulary; your prescriber can often substitute based on coverage

For Weight Loss Without Diabetes

If you’re seeking weight loss without a diabetes diagnosis, both Mounjaro and Ozempic are technically off-label. Your better options are:

• Zepbound — FDA-approved for obesity (tirzepatide, same as Mounjaro)
• Wegovy — FDA-approved for obesity (semaglutide, same as Ozempic at higher dose)
• Compounded semaglutide via telehealth — Most affordable option, ~$99–250/mo

Which Should You Choose?

Your Situation	Best Choice
Type 2 diabetes, want best blood sugar control	Mounjaro (tirzepatide)
Type 2 diabetes, insurance covers Ozempic	Ozempic (semaglutide)
Weight loss only, paying out of pocket	Compounded semaglutide (~$99/mo)
Weight loss, tried semaglutide, want more	Zepbound or compounded tirzepatide
Established cardiovascular disease + weight issues	Wegovy (proven MACE reduction in SELECT trial)